Combination treatment in vitro was significantly more effective in inhibiting tumor growth and SHH activation than either SMO and DNMT1 inhibitors alone, and this synergistic effect was seen in both murine and human cell models of SHH-MB sensitive to SMO inhibitors. This evidence concerns the gene DNMT1 and neoplasm.